

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

2190/49927

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING
A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

{Not Yet Assigned}

09/869696

INTERNATIONAL APPLICATION NO.

PCT/GB99/04268

INTERNATIONAL FILING DATE

30 December 1999

PRIORITY DATE CLAIMED

04 January 1999

TITLE OF INVENTION

P450/ACETAMINOPHEN GDEPT FOR CANCER TREATMENT

APPLICANT(S) FOR DO/EO/US

Donald DAVIES

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Item 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.

☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

International Search Report

Form PTO-1449

International Preliminary Examination Report

Form PCT/IB/306 - Notice of Recording of a Change

U.S. APPLICATION NO. (if known) 09/869896 (Not Yet Assigned)		INTERNATIONAL APPLICATION NO. PCT/GB99/04268	ATTORNEY'S DOCKET NUMBER 2190/49927	
17. [X] The following fees are submitted:			CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5):				
Search Report has been prepared by the EPO or JPO \$860.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) ... \$670.00				
No international preliminary examination fee paid to USPTO (37 CFR 1.482)				
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00				
Neither international preliminary examination fee (37 CFR 1.482) nor				
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 \$970.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482)				
and all claims satisfied provisions of PCT Article 33(2)-(4) \$92.00 \$96.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [X] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$ 130.00	
Claims	Number Field	Number Extra	Rate	
Total Claims	20-20=		X \$18.00	\$
Independent Claims	2-3=		X \$80.00	\$
Multiple dependent claims(s) (if applicable)			+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =			\$	
[X] Applicant Claims Small Entity Status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			\$ 495.00	
SUBTOTAL =			\$	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$	
TOTAL NATIONAL FEE =			\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$	
TOTAL FEE ENCLOSED =			\$ 495.00	
			Amount to be:	\$
			refunded	
			charged	\$
<p>a. [X] A check in the amount of \$ 495.00 to cover the above fees is enclosed.</p> <p>b. [] Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-1323. A duplicate copy of this sheet is enclosed.</p>				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO:				
CROWELL & MORING L.L.P.				
1200 G Street, N.W., Suite 700				
Washington, D.C. 20005				
Tel. No. (202) 628-8800				
Fax No. (202) 628-8844				
			SIGNATURE	
			J.D. Evans	
			NAME	
			26,269	
			REGISTRATION NUMBER	
			03 July 2001	
			DATE	

09/869696

JC18 Rec'd PCT/PTO 03 JUL 2001

Attorney Docket: 2190/49927
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DONALD DAVIES

Serial No.: PCT/GB99/04268

Filed: December 30, 1999

Title (AS AMENDED): P450/ACETAMINOPHEN GDEPT FOR CANCER TREATMENT

PRELIMINARY AMENDMENT

Box PCT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Preliminary to examination of the accompanying PCT U.S. National Stage patent application, kindly amend the application as follows:

In the claims:

Please cancel claims 1-20 and substitute therefor the following new claims 21-40:

21. (New) A method for treating cancer comprising:

- i) administering to a mammal an effective cancer-treating amount of at least one vector capable of transfecting at least one tumor cell, wherein said vector includes at least one P450 gene, or the effective part thereof, the expression of which is controlled by a promoter sequence, or the effective part thereof, which shows substantially tumor cell specific expression; and
- ii) administering to said mammal a therapeutically effective amount of acetaminophen.

22. (New) A method according to claim 21, wherein said mammal is human.

23. (New) A method according to claim 21, wherein said vector is a eukaryotic expression vector.

24. (New) A method according to claim 21, wherein said vector is a viral based vector.

25. (New) A method according to claim 24, wherein said viral based vector is a hybrid viral vector.

26. (New) A method according to claim 24, wherein said viral based vector comprises at least one member selected from the group consisting of adenovirus; retrovirus; adeno associated virus; herpes virus; lenti virus, and baculovirus.

27. (New) A method according to claim 21, wherein said tumor promoter comprises at least one promoter selected from the group consisting of TRP-1; HER2; HER3; ERBB2; ERBB3; CEA; MUC1; α -fetoprotein; Rous sarcoma virus long terminal repeat; cytomegalovirus promoter; murine leukemia long terminal repeat; simian virus 40 early and late promoters; herpes simplex virus thymidine kinase promoter; prostate specific antigen promoter (PSA); zilin gene promoter; pancreatic amylase promoter; tyrosinase related peptide promoter, and tumor rejection antigen precursor promoters.

28. (New) A method according to claim 27, wherein said promoter is a hybrid promoter comprising at least effective parts of at least two tumor cell specific promoters.

Serial No. PCT/GB99/04268

29. (New) A method according to claim 21, wherein said P450 gene is of mammalian origin.

30. (New) A method according to claim 29, wherein said P450 gene is of human origin.

31. (New) A method according to claim 30, wherein said human P450 gene is selected from the group consisting of CYP1A2; CYP2E1, and CYP3A4.

32. (New) A method according to claim 29, wherein said P450 gene is of rodent origin.

33. (New) A method according to claim 32, wherein said P450 gene is selected from the group consisting of rodent CYP1A2; rodent CYP2E1, and rodent CYP3A4.

34. (New) A method according to claim 21, wherein said tumor cell is a cancer cell of a cancer selected from the group consisting of breast; pancreatic; ovarian; cervical; lung; hepatic; renal; testicular; prostate gastrointestinal; glioma; melanoma; bladder; lymphoma; leukemia; epithelial, mesothelial, and retinal cancers.

35. (New) A vector capable of transfecting at least one tumor cell, wherein said vector includes at least one P450 gene, or an effective part thereof, the expression of which is controlled by a promoter sequence, or an effective part thereof; said vector showing substantially tumor cell specific expression.

36. (New) A composition of matter comprising acetaminophen in combination with a vector as defined in claim 35.

37. (New) A method of treating cancer comprising:

- i) administering to a mammal an effective amount of at least one vector, capable of transfecting at least one tumor cell, wherein said vector includes at least one P450 gene, or the effective part thereof, the expression of which is controlled by a promoter sequence, or the effective part thereof, which shows substantially tumor cell specific expression;
- ii) administering an effective amount of at least one agent capable of modulating the amount of glutathione in said mammal; and
- iii) administering a therapeutically effective amount of acetaminophen.

38. (New) A method according to claim 37, wherein said agent is at least one substance selected from the group consisting of methionine and acetylcysteine.

39. (New) A medicament for treating cancer comprising in combination a vector as defined in claim 35, and a therapeutically effective amount of acetaminophen.

40. (New) A kit for treating cancer comprising a vector as defined in Claim 35; acetaminophen; and, optionally, an excipient, carrier or diluent.

In the Abstract:

Please insert the Abstract found on the accompanying sheet.

Serial No. PCT/GB99/04268

REMARKS


The foregoing amendments are respectfully submitted to replace the European-style claims of the international application with claims of equivalent scope in better form for examination by the U.S. Patent and Trademark Office, and to add the required abstract of the disclosure.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #2190/49927).

Respectfully submitted,

July 3, 2001



J. D. Evans
Registration No. 26,269

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 628-8800
Facsimile No.: (202) 628-8844

[illegible][illegible][illegible]

Rec'd PCT/PTO 31 OCT 2001 #3
09/869696

Attorney Docket: 2190/49927
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DONALD DAVIES
Serial No.: 09/869,696
Filed: JULY 3, 2001
Title: P450/ACETAMINOPHEN GDEPT FOR CANCER TREATMENT

STATEMENT UNDER 37 C.F.R. 1.821(f)


Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The undersigned hereby states that the contents of the paper copy of the sequence listing in the above-identified U.S. National Stage application and the accompanying computer readable copy of the sequence listing are the same.

Respectfully submitted,

October 31, 2001



J. D. Evans
Registration No. 26,269

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:dcB

P15464W1.APP.txt
SEQUENCE LISTING

<110> ML Laboratories PLC

<120> Gene Therapy 1

<130> GDEPT

<140> PCT/GB99/04268

<141> 1999-12-30

<150> 9900009.3

<151> 1999-01-04

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 4214

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Base vector
sequence pEFPlink 6

<400> 1

gtttgacagc	ttatcatcga	ctgcacgggtg	caccaatgct	tctggcgctca	ggcagccatc	60
ggaagctgtg	gtatggctgt	gcaggctgta	aatcactgca	taattcgtgt	cgctcaaggc	120
gcactcccg	tctggataat	gttttttgcg	ccgacatcat	aacggttctg	gcaaattatc	180
tgaaatgagc	tggtgacaat	taatcatccg	gctcgtataa	tgtgtggaat	tgtgagcgga	240
taacaatttc	acacaggaaa	cagaccatgg	agcagaagct	gatttccgag	gaggacctgg	300
gatccgaatt	caagcttccc	ggggtcgaca	tcgattagac	tagtctagac	ggcggcggca	360
gcttggctgt	tttggcggat	gagagaagat	tttcagcctg	atacagatta	aatcagaacg	420
cagaaagcgt	ctgataaaac	agaatttgcc	tggcggcagt	agcgcgggtg	tcccacctga	480
ccccatgccg	aactcagaag	tgaacgcgcg	tagcgcggat	ggtagtgtgg	ggctctccca	540
tgcgagagta	gggaactgcc	aggcatcaaa	taaaacgaaa	ggctcagtcg	aaagactggg	600
cttttcgttt	tatctgttgt	ttgtcgggtg	acgctctcct	gagtaggaca	aatccgccgg	660
gagcggattt	gaacgtttgc	aagcaacggc	ccggagggtg	gcgggcagga	cgcccgccat	720
aaactgccag	gcatcaaatt	aagcagaagg	ccatcctgac	ggatggcctt	tttgcgtttc	780
tacaaactct	ttttgtttat	ttttctaaat	acattcaaat	atgtatccgc	tcatgagaca	840
ataaccctga	taaatgcttc	aataatattg	aaaaaggaag	agtatgagta	ttcaacattt	900
ccgtgtcgcc	cttattccct	tttttgcggc	attttgcctt	cctgtttttg	ctcaccaga	960
aacgctggtg	aaagtaaaag	atgctgaaga	tcagttgggt	gcacgagtgg	gttacatcga	1020
actggatctc	aacagcggta	agatccttga	gagttttcgc	cccgaagaac	gttttccaat	1080
gatgagcact	tttaaagttc	tgctatgtgg	cgcggtatta	tcccgtgttg	acgccgggca	1140
agagcaactc	ggtcgcgcga	tacactattc	tcagaatgac	ttggttgagt	actcaccagt	1200
cacagaaaag	catcttacgg	atggcatgac	agtaagagaa	ttatgcagt	ctgccataac	1260
catgagtgat	aacactgcgg	ccaacttact	tctgacaacg	atcggaggac	cgaaggagct	1320
aaccgctttt	ttgcacaaca	tgggggatca	tgtaactcgc	cttgatcgtt	gggaaccgga	1380
gctgaatgaa	gccataccaa	acgacgagcg	tgacaccacg	atgcctacag	caatggcaac	1440
aacggttgcg	aaactattaa	ctggcggaact	acttactcta	gcttcccggc	aacaattaat	1500
agactggatg	gaggcgggata	aagttgcagg	accacttctg	cgctcggccc	ttccggctgg	1560
ctggtttatt	gctgataaat	ctggagccgg	tgagcgtggg	tctcgcggta	tcattgcagc	1620
actggggcca	gatggttaagc	cctcccgtat	cgtagttatc	tacacgacgg	ggagtcaggc	1680
aactatggat	gaacgaaata	gacagatcgc	tgagataggt	gcctcactga	ttaagcattg	1740
gtaactgtca	gaccaagttt	atcatatata	acttttagatt	gatttaaaac	ttcattttta	1800
atttaaaagg	atctaggtga	agatcctttt	tgataatctc	atgaccaaag	ttccttaacg	1860
tgagttttcg	ttccactgag	cgtcagaccc	cgtagaaaag	atcaaaggat	cttcttgaga	1920
tccttttttt	ctgcgcgtaa	tctgtctgct	gcaaacaaaa	aaaccaccgc	taccagcggg	1980
ggtttggttg	ccggatcaag	agctaccaac	tctttttccg	aaggtaactg	gcttcagcag	2040
agcgcagata	ccaaataactg	tccttctagt	gtagccgtag	ttaggccacc	acttcaagaa	2100
ctctgtagca	ccgcctacat	acctcgctct	gctaactcctg	ttaccagtgg	ctgctgccag	2160
tggcgataag	tcgtgtctta	ccgggttggg	ctcaagacga	tagttaccgg	ataaggcgca	2220
gcggtcgggg	tgaacggggg	gttcgtgcac	acagcccagc	ttggagcgaa	cgacctacac	2280
cgaactgaga	tacctacagc	gtgagctatg	agaaagcgcc	acgcttcccc	aagggagaaa	2340

P15464W1.APP.txt

```

ggcggacagg tatccggttaa gcggcagggg cggaaacagga gagcgcacga gggagcttcc 2400
agggggaaac gcctgggtatc ttatagttc tgctggggtt cgccacctct gacttgagcg 2460
tcgatttttg tgatgctcgt cagggggggcg gagcctatgg aaaaacgcca gcaacgcggc 2520
ctttttacgg ttcttgccct tttgctggcc ttttgctcac atgttctttc ctgcttatc 2580
ccctgattct gtggataacc gtattaccgc ctttgagtga gctgataccg ctgcccag 2640
ccgaacgacc gagcgagcg agtcagtgag cgaggaagcg gaagagcgcc tgatgcggtg 2700
ttttctcctt acgcatctgt gcggtatttc acaccgcata tgggtgactc tcagtacaat 2760
ctgctctgat gccgcatagt taagccagta tacactccgc tatcgctacg tgactgggtc 2820
atggctgcgc cccgacaccc gccaacaccc gctgacgcgc cctgacgggc ttgtctgctc 2880
ccggcatccg cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagaggtt 2940
tcaccgtcat caccgaaacg cgcgaggcag cagatcaatt cgcgcgcaa ggcgaagcgg 3000
catgcattta cgttgacacc atcgaatggg gcaaaacctt tcgcggtatg gcatgatagc 3060
gcccgaaga gagtcaattc aggggtggga atgtgaaacc agtaacgtta tacgatgtcg 3120
cagagtatgc cgtgtctctc tatcagaccg tttccgcgt ggtgaaccag gccagccacg 3180
tttctgcgaa aacgcgggaa aaagtgaag cggcgatggc ggagctgaat tacattccca 3240
accgctggc acaacaactg gcgggcaaac agtcgttgct gattggcggt gccacctcca 3300
gtctggccct gcacgcgccg tcgcaaattg tcgcgcgat taaatctcg gccgatcaac 3360
tggtgcccag cgtggtgggt tcgatggtag aacgaagcgg cgtcgaagcc tgtaaagcgg 3420
cggtgcacaa tcttctcgcg caacgcgtca gtgggctgat cattaactat ccgctggatg 3480
accaggatgc cattgctgtg gaagctgcct gcactaatgt tccggcgta tttcttgatg 3540
tctctgacca gacacccatc aacagtatta ttttctcca tgaagacggt acgcgactgg 3600
gcgtggagca tctggtcgca ttgggtcacc agcaaatcgc gctgttagcg ggccattaa 3660
gttctgtctc ggcgctctg cgtctggctg gctggcataa atatctcact cgcaatcaaa 3720
ttcagccgat agcggaaacgg gaaggcgact ggagtgccat gtccggtttt caacaaacca 3780
tgcaaatgct gaatgagggc atcgttccca ctgcatgct ggttgccaac gatcagatgg 3840
cgctgggccc aatgcgcgcc attaccgagt ccgggctgcg cgttggtgcg gatattctcg 3900
tagtgggata cgacgatacc gaagacagct catgttatat cccgccgta accaccatca 3960
aacaggattt tcgctgctg gggcaaacca gcgtggaccg cttgctgcaa ctctctcagg 4020
gccaggcggg gaagggcaat cagctgttgc ccgtctcact ggtgaaaaga aaaaccaccc 4080
tggcgcccaa tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagctgg 4140
cacgacaggt ttcccgaactg gaaagcgggc agtgagcgca acgcaattaa tgtgagttag 4200
cgcgaattga tctg 4214

```



PCT09

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/869,696

DATE: 02/13/2002
 TIME: 07:59:22

Input Set : A:\P15464W1.APP.txt
 Output Set: N:\CRF3\02132002\I869696.raw

ENTERED

3 <110> APPLICANT: ML Laboratories PLC
 5 <120> TITLE OF INVENTION: Gene Therapy 1
 7 <130> FILE REFERENCE: GDEPT
 C--> 9 <140> CURRENT APPLICATION NUMBER: US/09/869,696
 C--> 10 <141> CURRENT FILING DATE: 2001-10-31
 12 <150> PRIOR APPLICATION NUMBER: 9900009.3
 13 <151> PRIOR FILING DATE: 1999-01-04
 15 <160> NUMBER OF SEQ ID NOS: 1
 17 <170> SOFTWARE: PatentIn Ver. 2.1
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 4214
 21 <212> TYPE: DNA
 22 <213> ORGANISM: Artificial Sequence
 24 <220> FEATURE:
 25 <223> OTHER INFORMATION: Description of Artificial Sequence: Base vector
 26 sequence pEFPlink 6
 28 <400> SEQUENCE: 1
 29 gtttgacagc ttatcatcga ctgcacgggtg caccaatgct tctggcgtca ggcagccatc 60
 30 ggaagctgtg gtatggctgt gcaggctcgt aatcactgca taattcgtgt cgctcaaggc 120
 31 gcactcccgt tctggataat gttttttgcg ccgacatcat aacggttctg gcaaataattc 180
 32 tgaaatgagc tgttgacaat taatcatccg gctcgtataa tgtgtggaat tgtgagcggg 240
 33 taacaatttc acacaggaaa cagaccatgg agcagaagct gatttccgag gaggacctgg 300
 34 gatccgaatt caagcttccc ggggtcgaca tcgattagac tagtctagac ggcggcggca 360
 35 gcttggctgt tttggcggat gagagaagat tttcagcctg atacagatta aatcagaacg 420
 36 cagaagcggg ctgataaaac agaatttgcc tggcggcagt agcgcggtgg tcccacctga 480
 37 ccccatgccg aactcagaag tgaaacgccg tagcgccgat ggtagtgtgg ggtctcccca 540
 38 tgcgagagta gggaaactgcc aggcattcaa taaaacgaaa ggctcagtcg aaagactggg 600
 39 cctttcgttt tatctgttgt ttgtcgggtg acgctctcct gagtaggaca aatccgcccg 660
 40 gagcgatttt gaacgttgcg aagcaacggc ccggagggtg gcgggcagga cgcgcccat 720
 41 aaactgccag gcatcaaatt aagcagaagg ccatcctgac ggatggcctt tttgcgtttc 780
 42 tacaaactct ttttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca 840
 43 ataaccctga taaatgcttc aataatattg aaaaaggaag agtatgagta ttcaacattt 900
 44 ccgtgtcgcc cttattccct tttttgcgcc attttgcctt cctgtttttg ctcaccacga 960
 45 aacgctgggt aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga 1020
 46 actggatctc aacagcggta agatccttga gagttttcgc cccgaagaac gttttccaat 1080
 47 gatgagcact tttaaagttc tgctatgtgg cgcggtatta tcccgtgttg acgcccggca 1140
 48 agagcaactc ggtgcgcgca tacactattc tcagaatgac ttggttgagt actcaccagt 1200
 49 cacagaaaag catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac 1260
 50 catgagtgat aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct 1320
 51 aaccgctttt ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga 1380
 52 gctgaatgaa gccataccaa acgacgagcg tgacaccacg atgcctacag caatggcaac 1440
 53 aacgttgccg aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat 1500
 54 agactggatg gaggcggata aagttgcagg accactttctg cgctcggccc ttccggtctg 1560

RAW SEQUENCE LISTING

DATE: 02/13/2002

PATENT APPLICATION: US/09/869,696

TIME: 07:59:22

Input Set : A:\P15464W1.APP.txt

Output Set: N:\CRF3\02132002\I869696.raw

```

55 ctggttttatt gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc 1620
56 actggggcca gatggttaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc 1680
57 aactatggat gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg 1740
58 gtaactgtca gaccaagttt actcatatat acttttagatt gatttaaaac ttcatTTTTA 1800
59 atttaaaagg atctaggtga agatcctttt tgataatctc atgaccaaaa tcccttaacg 1860
60 tgagtttttcg ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga 1920
61 tctttttttt ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaaccg taccagcggg 1980
62 ggtttgtttg ccgatcaag agctaccaac tcttttttcg aaggtaactg gcttcagcag 2040
63 agcgcagata ccaaatactg tctttctagt gtagccgtag ttaggccacc acttcaagaa 2100
64 ctctgtagca ccgcctacat acctcgctct gctaactctg ttaccagtgg ctgctgccag 2160
65 tggcgataag tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca 2220
66 gcggtcgggc tgaacggggg gtctgtgcac acagcccagc ttggagcgaa cgacctacac 2280
67 cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgcttcccg aaggagagaa 2340
68 ggcggacagg tatccggtaa gcggcagggg cggaacagga gagcgacga gggagcttcc 2400
69 agggggaaac gcctggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg 2460
70 tcgatttttg tgatgctcgt cagggggggc gagcctatgg aaaaacgcca gcaacgcggc 2520
71 ctttttacgg ttctggcct tttgctggcc ttttgcctac atgttctttc ctgcgttatc 2580
72 ccctgattct gtgataaacc gtattaccgc ctttgagtga gctgataacc ctcgcccgag 2640
73 ccgaacgacc gagcgcagcg agtcagttag cgaggaagcg gaagagcgcc tgatgcggta 2700
74 ttttctcctt acgcatctgt gcggtatttc acaccgcata tgggtgactc tcagtacaat 2760
75 ctgctctgat gccgcatagt taagccagta tacactccgc tatcgctacg tgactgggtc 2820
76 atggctgcgc cccgacaccc gccaaacacc gctgacgcgc cctgacgggc ttgtctgctc 2880
77 ccgcatcccg cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagagggtt 2940
78 tcaccgtcat caccgaaacg cgcgaggcag cagatcaatt cgcgcgcgaa ggcgaagcgg 3000
79 catgcattta cgttgacacc atcgaatggt gcaaaacctt tcgcggtatg gcatgatagc 3060
80 gcccggaaga gagtcaattc aggggtggtga atgtgaaacc agtaacgtta tacgatgtcg 3120
81 cagagtatgc cgggtgtctt tatcagaccg tttcccgcgt ggtgaaccag gccagccacg 3180
82 tttctgcgaa aacgcgggaa aaagtggaag cggcgatggc ggagctgaat tacattccca 3240
83 accgcgtggc acaacaactg gcgggcaaac agtcgttgct gattggcgtt gccacctcca 3300
84 gtctggccct gcacgcgcgc tcgcaaattg tcgcggcgat taaatctcgc gccgatcaac 3360
85 tgggtgccag cgtggtggtg tcgatggtag aacgaagcgg cgtcgaagcc tgtaaagcgg 3420
86 cgggtcacaa tcttctcgcg caacgcgtca gtgggctgat cattaactat ccgctggatg 3480
87 accaggatgc cattgctgtg gaagctgcct gcaactaatg tccggcggtta tttcttgatg 3540
88 tctctgacca gacacccatc aacagtatta ttttctccca tgaagacggt acgcgactgg 3600
89 gcgtggagca tctggtcgca ttgggtcacc agcaaategc gctgttagcg ggccattaa 3660
90 gttctgtctc ggcgctctg cgtctggtg gctggcataa atatctcact cgcaatcaaa 3720
91 ttcagccgat agcggaacgg gaaggcgact ggagtgccat gtccggtttt caacaaacca 3780
92 tgcaaatgct gaatgagggc atcgttccca ctgcatgct gggtgccaac gatcagatgg 3840
93 cgtctggcgc aatgcgcgcc attaccgagt ccgggctgcg cgttggtgcg gatattctcg 3900
94 tagtgggata cgacgatacc gaagacagct catgttatat cccgcggtta accaccatca 3960
95 aacaggatth tcgctgtctg gggcaaacca gcgtggaccg cttgctgcaa ctctctcagg 4020
96 gccaggcggg gaagggcaat cagctgttgc ccgtctcact ggtgaaaaga aaaaccaccc 4080
97 tggcgcccaa tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagctgg 4140
98 cacgacaggt ttcccgactg gaaagcgggc agtgagcgca acgcaattaa tgtgagttag 4200
99 cgcgaattga tctg 4214

```

VERIFICATION SUMMARY

DATE: 02/13/2002

PATENT APPLICATION: US/09/869,696

TIME: 07:59:23

Input Set : A:\P15464W1.APP.txt

Output Set: N:\CRF3\02132002\I869696.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application Number
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date

GENE THERAPY -1

1. Field of the Invention

- 5 This invention relates to a form of gene therapy known as genetically directed enzyme prodrug therapy (GDEPT).

2. Background of the Invention.

- 10 Current therapies to treat cancer involve, amongst other things, radiation therapy and chemotherapy each of which, although effective at retarding the growth of cancer cells, have significant disadvantages since each treatment is typically selective for cells that are actively dividing. Consequently, normal dividing cells are also destroyed resulting in significant undesirable side effects, such as nausea and
15 immunosuppression, the latter of which can lead to complications of secondary infections. In recent years research has focussed on providing selective treatments which lessen these undesirable side effects. One such therapy is GDEPT ^{1,2}.

- GDEPT is of particular interest with respect to the treatment of cancer in that it offers
20 advantages over conventional chemotherapeutic methods of cancer treatment. In such conventional methods the drugs administered to the patient attack not only the targeted cancer cells but also normal cells. Destruction of cancer cells is achieved at the expense of inflicting damage on normal cells, creating serious side-effects. In treatment of cancer by GDEPT the objective is to create an anti-cancer drug in situ
25 within the cancer cell while creating little or none in normal cells, thereby attacking the cancer cells while leaving the normal cells substantially unaffected. This is typically achieved by administration to the patient of a vector containing a gene for an enzyme which can convert a relatively non-toxic substance (commonly referred to as a prodrug) into a cytotoxic agent. The vector also contains a promoter, ie a DNA
30 sequence constituting a switch for the gene, this promoter being responsive to a regulatory protein found solely in the cancer cells or to a greater extent in the cancer

cells than in normal cells. The gene is thus expressed substantially in the cancer cells so it is only (or mainly) in the cancer cells that the enzyme is produced and that conversion of the prodrug to the cytotoxic agent takes place. Formation of the cytotoxic agent therefore takes place primarily in the cancer cells. In this way the cancer cells are selectively attacked, with relatively little damage to normal cells.

In one example of the use of GDEPT in cancer treatment, the prodrug is 5-fluorocytosine (5-FC). 5-FC is itself relatively non-toxic to human cells but can be converted into a potent anti-cancer drug, 5-fluorouracil (5-FU), by the enzyme cytosine deaminase. A bacterial gene which expresses cytosine deaminase is incorporated in a viral vector in association with a promoter which is responsive to a regulatory protein that is characteristic of the particular type of cancer cell under attack. For instance, in treating breast cancer the promoter could be one which is responsive to the regulatory protein ERBB2 or in treating liver cancer one which is responsive to α -fetoprotein.

In known GDEPT techniques, difficulty has been encountered in achieving as high a degree of selectivity as is desirable, (ie in destroying cancer cells while limiting the damage to normal cells). This is at least partly due to the fact that normal cells may come under attack from cytotoxic agents which have been formed in the cancer cells but have found their way out of those cells, for example when the cells break down under the cytotoxic action of the drug.

In addition, some chemotherapeutic agents are selective for particular cell- cycle phases (eg G1, S, G2 or mitosis). It is desirable to provide chemotherapeutic agents that are not so restricted in their effects and can kill cells irrespective of the cell-cycle stage.

3. Detailed Background of the Invention

3.1. Acetaminophen as a Prodrug

5 Acetaminophen is a widely used mild pain reliever and antipyretic. However, it is a potentially dangerous drug in that an overdose of it can cause serious, even fatal, damage to the liver³. This is due to the fact that liver cells express a gene for a P450 enzyme, specifically CYP1A2, also to a much lesser extent CYP 2E1 and CYP 3A4. This enzyme can convert acetaminophen into a metabolite, N-
10 acetylbenzoquinoneimine (NABQI), which is highly cytotoxic. For standard dosages of acetaminophen, the toxicity of NABQI is countered in the liver by conversion of NABQI into a non-toxic substance by reaction with glutathione, a normal component of human cells^{4,5}. The supply of glutathione is however insufficient to deal with the large amounts of NABQI formed in liver cells after an overdose of acetaminophen
15 and the cells are therefore then damaged or destroyed.

When acetaminophen constitutes the prodrug in GDEPT, the vector administered contains a gene for a p450 enzyme^{7,8}, preferably CYP1A2, and the cytotoxic agent formed in the cancer cells is NABQI. In contrast to other cytotoxic agents, NABQI
20 causes little or no systemic toxicity.

3.2 Tumour Specific Gene Expression

It might have been expected that the use of acetaminophen as a prodrug in GDEPT
25 would be impractical. Selective expression of the gene for the enzyme CYP1A2 in cancer cells could be effected by administration of a vector containing that gene in association with a promoter which is responsive to a regulatory protein found only in the cancer cells. The enzyme CYP1A2, created as a result of the entry into cells of that vector, would then convert acetaminophen into NABQI in the cancer cells and
30 damage or destroy them. As in conventional GDEPT using prodrugs other than acetaminophen, selectivity between cancer cells and normal cells would be achieved

because entry of the vector into normal cells would not cause expression of the CYP1A2 gene contained in the vector since the normal cells do not contain the regulatory protein which activates the chosen promoter for the gene. In general, the normal cells would therefore not contain the enzyme CYP1A2 and would be unaffected by the presence of acetaminophen because in such cells it would not undergo intracellular conversion to NABQI. However, as mentioned above, normal liver cells naturally express a gene for CYP1A2. It would therefore be expected that administering a dose of acetaminophen high enough to create a level of NABQI in cancer cells capable of killing such cells could also result in the creation of sufficient NABQI in the normal liver cells to kill them too. Surprisingly, this is not so, probably due to a difference in the glutathione content of normal liver cells and that of cancer cells. It appears that most cancer cells may contain only about one-fifth of the glutathione present in normal liver cells. The concentration of the cytotoxic NABQI is therefore kept much lower in the normal liver cells than in the cancer cells because more NABQI can be detoxified, by combination of NABQI with glutathione, in the normal liver cells than in the cancer cells.

3.4 Gene Therapy Vectors & P450 Genes

The vector used in the present invention is one containing a gene for a p450 enzyme, preferably for CYP1A2, and a promoter which acts as a switch for that gene and which is responsive to a regulator protein characteristic of the type of cancer being addressed. The gene can be derived from human DNA (Ikeyak et al Molecular Endocrinology (1989), 3: 1399- 1408). However, it may be advantageous to use a P450 gene derived from non-human DNA, for example mouse DNA or hamster DNA. The P450 enzyme generated by the mouse gene is relatively unaffected by certain compounds, for example furaphylline, which act as inhibitors of the form of the enzyme CYP1A2 generated by the human gene. Administration of such inhibitors makes it possible to raise the dosage of acetaminophen above the normally safe dosage; an inhibitor such as furaphylline can protect the normal liver cells by inhibiting the form of P450 generated by expression in those cells of the human gene,

while having little or no effect on the form of P450 generated by expression of the mouse gene in the cancer cells. The level of NABQI in the normal liver cells is therefore diminished by such inhibitors while the level of NABQI in the cancer cells is relatively unaffected by the inhibitors.

5

With regard to non-viral delivery, synthetic uptake of DNA into mammalian cells can be facilitated by condensing it with lipids, proteins or peptides. These include, by example and not by way of limitation, polymers, dendrimers and cationic lipid delivery means (eg liposomes).

10

Liposomes are lipid based vesicles which encapsulate a selected therapeutic agent which is then introduced into a patient. The liposome is manufactured either from pure phospholipid or a mixture of phospholipid and phosphoglyceride. Typically liposomes can be manufactured with diameters of less than 200nm, this enables them to be intravenously injected and able to pass through the pulmonary capillary bed.

15

Furthermore the biochemical nature of liposomes confers permeability across blood vessel membranes to gain access to selected tissues. Liposomes do have a relatively short half-life. So called STEALTH^R liposomes have been developed which comprise liposomes coated in polyethylene glycol (PEG). The PEG treated liposomes

20

have a significantly increased half-life when administered intravenously to a patient. In addition STEALTH^R liposomes show reduced uptake in the reticuloendothelial system and enhanced accumulation selected tissues. In addition, so called immuno-liposomes have been develop which combine lipid based vesicles with an antibody or antibodies, to increase the specificity of the delivery of the DNA vector to a selected cell/tissue.

25

The use of liposomes as delivery means is described in US 5580575 and US 5542935.

Bacteria such as salmonella could be a more novel delivery vehicle. The DNA can also be coated on to microprojectiles and fired into the nuclei or target cells by a gene gun.

5 3.4 DNA Transfection

Many methods have been developed over the last 30 years to facilitate the introduction of DNA into cells which have greatly assisted, *inter alia*, our understanding of the control of gene expression.

- 10 Conventional methods to introduce DNA into cells are well known in the art and typically involve the use of chemical reagents, cationic lipids or physical methods. Chemical methods which facilitate the uptake of DNA by cells include the use of DEAE -Dextran (Vaheri and Pagano Science 175: p434) . DEAE-dextran is a
- 15 negatively charged cation which associates and introduces the DNA into cells but which can result in loss of cell viability. Calcium phosphate is also a commonly used chemical agent which when co-precipitated with DNA introduces the DNA into cells (Graham et al Virology (1973) 52: p456).
- 20 The use of cationic lipids (eg liposomes (Felgner (1987) Proc.Natl.Acad.Sci USA, 84:p7413) has become a common method since it does not have the degree of toxicity shown by the above described chemical methods. The cationic head of the lipid associates with the negatively charged nucleic acid backbone of the DNA to be introduced. The lipid/DNA complex associates with the cell membrane and fuses
- 25 with the cell to introduce the associated DNA into the cell. Liposome mediated DNA transfer has several advantages over existing methods. For example, cells which are recalcitrant to traditional chemical methods are more easily transfected using liposome mediated transfer.
- 30 More recently still, physical methods to introduce DNA have become effective means to reproducibly transfect cells. Direct microinjection is one such method which can deliver DNA directly to the nucleus of a cell (Capecchi (1980) Cell, 22:p479). This

allows the analysis of single cell transfectants. So called "biolistic" methods physically shoot DNA into cells and/or organelles using a particle gun (Neumann (1982) EMBO J, 1: p841). Electroporation is arguably the most popular method to transfect DNA. The method involves the use of a high voltage electrical charge to momentarily permeabilise cell membranes making them permeable to macromolecular complexes. However physical methods to introduce DNA do result in considerable loss of cell viability due to intracellular damage. These methods therefore require extensive optimisation and also require expensive equipment.

What is apparent from the above is that transfection of cells, either transiently or stably is a routine procedure undertaken by the man skilled in the art and is extensively referenced in academic publications, laboratory manuals and reference books. We have used both transient and stably transfected cell-lines to analyse the use of acetaminophen in GDEPT.

4. Statement of Invention

It is an object of the invention to provide a cancer therapy which reduces undesirable side effects of conventional cancer treatments.

It is a further object of the invention to provide a gene therapy based cancer treatment which targets cancer cells.

According to a first aspect of the invention there is provided a cancer therapy comprising;

- i) administering to a mammal an effective amount of at least one vector capable of transfecting at least one tumour cell characterised in that said vector includes at least one P450 gene, or an effective part thereof, the expression of which is controlled by a promoter sequence, or the effective part thereof, which shows substantially tumour cell specific expression; and

- ii) administering a therapeutically effective amount of at least acetaminophen, or a structurally related derivative thereof.

In a preferred method of the invention said mammal is human.

5

In a further preferred method of the invention said vector is an expression vector conventionally adapted for eukaryotic expression.

10

Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive.

15

Promoter is an art recognised term and, for the sake of clarity, includes the following features which are provided by example only, and not by way of limitation. Enhancer elements are *cis* acting nucleic acid sequences often found 5' to the transcription initiation site of a gene (enhancers can also be found 3' to a gene sequence or even located in intronic sequences). Enhancers function to increase the rate of transcription of the gene to which the enhancer is linked. Enhancer activity is responsive to *trans* acting transcription factors (polypeptides) which have been shown to bind specifically to enhancer elements. The binding/activity of transcription factors (please see Eukaryotic Transcription Factors, by David S Latchman, Academic Press Ltd, San Diego) is responsive to a number of environmental cues which include, by example and not by way of limitation, intermediary metabolites (eg glucose, lipids) or environmental effectors (eg light, heat,).

20
25

Promoter elements also include so called TATA box and RNA polymerase initiation site (RIS) sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, *inter alia*, to facilitate transcription initiation selection by RNA polymerase.

30

Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic cell.

- 5 In addition adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination/polyadenylation sequences. This also includes the provision of internal ribosome entry sites (IRES) which function to maximise expression of vector encoded genes arranged in bicistronic or multicistronic expression cassettes.

10

These adaptations are well known in the art. There is a significant amount of published literature with respect to expression vector construction. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F
15 (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK.

- In yet a further preferred method of the invention said vector is a viral based vector. Ideally said viral vector is selected from the following: adenovirus; retrovirus; adeno
20 associated virus; herpesvirus; lentivirus; baculovirus.

- Viral based vectors according to the invention may also include hybrid viral vectors which include advantageous features of selected viruses which facilitate, for example and not by way of limitation, viral infectivity, replication or expression of genes
25 carried by said hybrid vector.

- In a still further preferred method of the invention said promoter sequence is preferably selected from at least one of the following: TRP-1; HER2; HER3; ERBB2; ERBB3; CEA; MUC-1; α -fetoprotein; Rous sarcoma virus long terminal
30 repeat; cytomegalovirus promoter; murine leukaemia long terminal repeat; simian virus 40 early and late promoters; herpes simplex virus thymidine kinase promoter;

prostate specific antigen promoter (PSA); zilin gene promoter; pancreatic amylase promoter; tyrosinase related peptide promoter; tumour rejection antigen precursor promoters.

- 5 In yet a further preferred method of the invention said P450 gene is of mammalian origin; ideally human. More ideally still said P450 gene is human CYP1A2. Alternatively said P450 gene is either human CYP2E1 or CYP3A4.

- 10 In yet still a further preferred method of the invention said P450 is of non-human origin. Ideally said P450 gene is derived from a rodent. More ideally still said rodent P450 gene is selected from homologous rodent genes encoding CYP1A2; CYP2E1; or CYP3A4.

- 15 GDEPT which uses rodent homologues of P450 are advantageous since inhibitors of human CYP1A2, for example, furaphylline, can be used in conjunction with acetaminophen. As noted previously, the rodent homologue of CYP1A2, is resistant to this inhibitor than the human form of the enzyme. This would therefore enable the use of elevated levels of acetaminophen since toxic amounts of NABQI would not be generated in the liver.

- 20 The administration of the vector according to the invention to the mammal is by conventional techniques. Typically this includes, by example and not by way of limitation, intravenous, intramuscular or intraperitoneal injection; or direct injection into the tumour tissue.

- 25 In yet a still further preferred method of the invention said tumour cell is selected from at least one on the following cancers: breast; pancreatic; ovarian; cervical; lung; hepatic; retinal; renal; testicular; prostate; gastrointestinal; glioma; melanoma; bladder; lymphoma; leukaemia; epithelial; mesothelial;

30

In yet still a further preferred method of the invention there is provided the use of acetaminophen in the manufacture of a medicament for the treatment of cancer.

According to a further aspect of the invention there is provided a cancer therapy
5 comprising:

- i) administering to a mammal an effective amount of at least one vector, capable of transfecting at least one tumour cell, characterised in that said vector includes at least one P450 gene, or an effective part thereof, the expression of
10 which is controlled by a promoter sequence, or the effective part thereof, which shows substantially tumour cell specific expression;
- ii) administering an effective amount of at least one agent capable of modulating the amount of glutathione in said mammal; and
- iii) administering a therapeutically effective amount of acetaminophen, or a
15 structurally related derivative thereof.

Agents capable of increasing glutathione in the liver are well known in the art and include, by example and not by way of limitation, methionine, acetylcysteine.

20 An embodiment of the invention will now be described, by example only, and with reference to the following Table and Figures;

Table 1 represents the bystander effect on viability produced by incubating H1A2 MZ cells (stably transfected with human CYP1A2) with various cell lines in the
25 presence of acetaminophen. Tumour cells or V79 MZ cells (non transfected, parental cells) were co-cultured overnight with various mixtures of H1A2 MZ cells (as indicated in the Table), washed with PBS and incubated with 4 mM acetaminophen in PBS for 6 h at 37°C. the cells were then washed once with PBS and maintained for either 24 or 48 h in culture medium appropriate to each cell type, as detailed in
30 the Methods section. At 0, 6, 24 or 48 h the cells were washed in PBS and viability of the mixed cell population determined by trypan blue exclusion. The data shown

are mean values \pm SEM of 4 separate determinations. Statistical significance was determined at each time point by comparing viability measurements in the mixed cell populations with both the viability determined at 0 h and in the absence of H1A2 MZ cells in the mixture 2 x 2 contingency tables using the 2-tailed Chi-squared test with

5 Yate's correction. Viability was determined in a total of 1500 cells at each time point. Levels of significance are indicated as ** $p < 0.001$; *** $p < 0.0001$;

Figure 1 is a graphical representation of an acetaminophen titration showing the sensitivity of COS cells transiently transfected with a vector incorporating mouse

10 CYP1A2 and non-transfected control COS cells. Cell viability is monitored by tritiated thymidine incorporation;

Figure 2 is a cell viability time course of COS cells transiently transfected with mouse CYP1A2 and non-transfected control COS cells over a 24hr period.

15 Acetaminophen concentration is 10mM. Cell viability is monitored by tritiated thymidine incorporation;

Figure 3 represents the effect of acetaminophen on the viability of stably transfected V79 MZ and H1A2 MZ cells. V79 MZ cells (stippled bars) and H1A2 MZ cells

20 (filled bars) were allowed to adhere to the wells of tissue culture plates overnight, washed with PBS and then incubated with various concentrations of acetaminophen for 6 h at 37 °C. Viability was determined by the ability of cells to exclude trypan blue. Data is represented as the mean \pm SEM of 4 separate determinations and analysed by comparing the viability in H1A2 MZ cells with V79 MZ cells at each

25 concentration of acetaminophen using the 2-tailed unpaired Student's t-test. Levels of significance are indicated as * $p < 0.01$; *** $p < 0.0001$;

Figure 4 represents the bystander effect on viability produced by incubating stably transfected, acetaminophen-activating H1A2 MZ cells with non- transfected parental

30 V79 MZ cells. V79 MZ cells were co-cultured overnight with various mixtures of H1A2 MZ cells, washed with PBS and then incubated with 4 mM acetaminophen for

up to 6 h at 37°C. The cells were then washed in PBS and the viability of the mixed cell population determined by trypan blue exclusion. The cultures comprised V79 MZ cells only (open squares), and V79 MZ cells mixed with 5% (solid squares), 10% (open triangles), 25% (open circles) and 50% (solid circles) H1A2 MZ cells. In addition, the viability of H1A2 MZ cells in the presence (crosses) and absence (solid triangles) of acetaminophen is shown. Data is represented as the mean \pm SEM of 4 separate determinations. Statistical analysis of the data at the 6 h time point is presented in Table 1.

Figure 5 represents the sub-cloning procedure to create the expression vector used in the transient transfection experiments; and

Figure 6 is the DNA sequence of the vector pEFPlink 6.

5. Materials and Methods

5.1.1. Recombinant DNA Techniques

The CYP1A2 cDNA is cloned downstream of a 544 bp fragment of the proximal 5' flanking region of the human ERBB2 gene in pBluescript II SK+ and then the chimeric minigene (ERBB2 promoter-CYP1A2 cDNA) is subcloned into a variety of eukaryotic expression vectors including:-

(a) the plasmid pPolyA (based on the commercial vector pcDNA [InVitrogen] from which the CMV promoter has been excised). Transfection is performed by application of plasmid DNA in the presence of cationic liposome complexes, either commercially obtained reagents such as Lipofectin (Life Technologies) or novel experimental agents (Genzyme). In order to allow for selection of genetically transformed clones the ERBB2-CYP1A2 plasmid is cotransfected at a 9:1 molar ratio with pSV2neo which encodes resistance to geneticin.

(b) the double copy retrovirus N2A, which allows conditional expression of the insert outside the transcription unit driven by the retroviral long terminal repeat promoter. Amphotropic retroviral stock is produced by packaging of the virus in GP + env AM12 cells.

5

(c) the adeno-associated virus vector psub 201, which when cotransfected into adenovirus-expressing cells together with pAAV/Ad leads to production of recombinant AAV that allows conditional expression of the insert in target cells.

10 The target cells in this example are human breast and pancreatic cancer cell lines which either over-express ERBB2 due to transcriptional upregulation or express normal (undetectable) levels.

5.1.2 Vector Construction for Transient Cell Transfection

15

A summary of the sub-cloning procedure is set-out in Figure 5. Briefly, the following steps were undertaken. CYP1A2 was subcloned from pCRTMBac (Invitrogen) by digestion with restriction enzymes EcoR1 and BamH1. This fragment was sub-cloned into EcoR1/BamH1 digested pEFPlink.6 which is derived from pEFPlink2 (Marais *et al* (1995) EMBO J 14: 3136 – 3145). pEFPlink.6 is altered by the selective removal of restriction sites and the provision of a more versatile multiple cloning site. The sequence of pEFPlink6 is given in Figure 4.

20

The sub-cloned CYP1A2 gene was sequenced to confirm its identity to the published CYP1A2 sequence. The vector containing the CYP1A2 gene is called pEF+cyp+.

25

Non-coding 5' and 3' sequences were then removed to generate restriction sites which facilitate the sub-cloning of CYP1A2 into a eukaryotic expression vector. CYP1A2 was PCR amplified and cut with Cla1 and Sma 1 and sub-cloned back into pEF+cyp+ to replace the original CYP1A2 gene. This removes much of the 3' untranslated region of the . This vector is called pEF+cyp. The 5' leader sequence

30

was deleted in the following way. Sequence specific primers were used to to amplify CYP1A2 from pEF+Plink+ and create a Nco1 site. It is preferable to use the ATG initiation codon in the Nco1 site to ensure efficient translation initiation of CYP1A2. The amplified fragment was cut with Nco 1 and HindIII and subcloned into
5 pEFPlink6. This vector was sequenced to confirm the sub-cloning. pEFPlink was cut with Nco1 and HindIII and subcloned into pEF+cyp. This vector was called pEFcyp1A2.

This modified CYPA12 cDNA was then subcloned into the eukaryotic expression
10 vector pMCEF which is derived from pEFPlink2 and contains the NeoR gene allowing selection in G418. The expression of the modified CYP1A2 cDNA is under the control of the elongation factor 1 α promoter , (Marais *et al* Cancer Research (1996) 56: 4735 – 42). This was done by digestion of pEFcypA2 with Nco1 and Spe 1 and sub-cloning the fragment containing the modified CYP1A2 into pMCEF to
15 generate the expression vector pMCEFcyp1A2.

pMCEFcyp1A2 incorporating mouse CYP1A2 was used in transient transfection experiments described below.

20 5.2 Transient Cell Transfection Using LipofectAMINE

LipofectAMINE (LPA)(Gibco BRL UK) is a lipid reagent that transfers DNA into cells and has proven to be very successful for transiently transfecting cells. We have found that we can achieve transfection frequencies approaching 50% (depending on
25 cell-line and DNA construct). This compares very favourably with DEAE – dextran transfection which can only achieve approximately 0.5-2.5% efficiency. We estimate that LPA only results in 5% cell death when compared to 50% cell death when using DEAE- dextran.

30 COS cells are plated at 1.5×10^5 per well in 6 well tissue culture dishes the evening before transfection. Cells are left to grow overnight in Dulbecco-Vogt's Modified

Eagles Medium (DMEM) supplemented with 10% foetal calf serum, 2mM L-glutamine, penicillin(100U/ml) and streptomycin (100µg/ml). All tissue culture reagents can be obtained from Gibco BRL, Paisley, UK.

- 5 LPA/DNA complexes are prepared in accordance with the manufactures instructions. Briefly the following steps are undertaken. On the day of the transfection experiment dilutions of vector DNA are prepared in PBSA (0.4g KCl , 8.0g NaCl, 0.2g KH₂PO₄, 1.15g Na₂HPO₄ per litre) containing 0.5% (w/v) albumin . It is important not to use polypropylene reaction tubes as the LPA/DNA complex will adhere to the plastic.

10

Vector DNA is prepared at 0.4- 0.6 µg per transfection in 16µl of PBSA. Typically a stock of vector DNA is prepared at 0.025µg/ml in PBSA for use in transfection experiments. In experiments where more than one vector is used the same concentration of DNA is to be used and the volume adjusted accordingly. Note that

15 when using multiple vectors it is important to mix the vectors prior to addition of LPA.

20

Typically, when preparing the LPA/DNA complex squares approximately 1cm x 1cm are marked onto the bottom of a petri dish corresponding to the number of transfection to be conducted. 10 – 12 µl PBSA is placed into the centre of each marked square to which 4-6 µl of LPA is added to give a total volume of 14-16µl. To this reaction mix is added 16µl stock vector DNA and the LPA/DNA complex is thoroughly mixed by passage through a micropipette tip by sucking the reaction mixture up and down 6 – 8 times. The reaction mixture is then left in the covered

25 petri dish for approximately 15 minutes.

30

During this incubation period, cells to be transfected are washed with serum free medium and then 800µl of serum free medium added prior to addition of the complexed LPA/DNA.

To the LPA/DNA complex, 200µl of serum free medium is added to each LPA/DNA sample which is then gently added to the cells over a period of 3 – 4 seconds. Cells are returned to a 37°C CO₂ incubator for 6 hours. Cells are washed twice in medium and 2.5ml of fresh medium is added to the cultures. Cultures can then be assayed at any time to monitor transgene expression.

The above described method provides reliable, high level expression of transgenes carried by vector DNA. The method is readily undertaken by the man skilled in the art.

5.3 Western Blotting

The level of expression of CYP1A2 is measured by Western blot analysis utilizing anti-peptide antibodies described in the literature (Edwards RJ et al, Biochem Pharmacol 1993; 46: 213-220 and Murray BP et al, Carcinogenesis 1993; 14: 585-592). These antibodies bind specifically to CYP1A2 in human liver microsomal fraction. In addition, one of the antibodies has been shown to bind readily to CYP1A2 expressed in a human B lymphoblastoid cell line transfected with a plasmid vector expressing human CYP1A2. In these cells the level of expression of human CYP1A2 was similar to that found in human liver, ie 8 pmols per mg protein (Edwards RJ et al, Carcinogenesis 1994; 15: 829-836). Microsomal fractions are prepared from tumour cells transfected with human CYP1A2, or cells transfected with an unrelated gene, eg cytosine deaminase, in the same vectors. Washed cells are disrupted using a Dounce homogeniser and the microsomal fraction prepared by ultracentrifugation and stored frozen at -80°C as described previously. Western blotting of microsomal fractions is performed as described previously (Boobis AR et al, Br J Clin Pharmacol 1980; 9: 11-19) employing enhanced chemiluminescence to maximise sensitivity.

5.4 Biochemical Activity of CYP1A2

5 In addition, the functional activity of expressed human CYP1A2 is determined in the
tumour cells by measuring the rate of *O*-deethylation of phenacetin. At an
appropriate substrate concentration (4 μ M) this reaction is specifically catalysed by
CYP1A2 in human liver microsomal fraction. Tumour cell microsomal fractions
prepared as described above are incubated at 37°C in the presence of NADPH and
10 the production of acetaminophen is determined by gas chromatography/negative ion
chemical ionisation mass spectrometry using deuterated acetaminophen as internal
standard. This highly sensitive assay easily measures CYP1A2 activity in small
quantities (<10 μ g) of human liver microsomal fraction which typically has an
activity of 70 pmols/min/mg protein.

5.5 Cell Viability

Two methods were employed to monitor cell viability; exclusion of trypan blue by
viable cells followed by cell counting; and incorporation of tritiated thymidine as a
20 measure of DNA synthesis.

5.5.1 Trypan Blue Exclusion

For cell viability experiments 200,000 cells per well were plated on 12 well plates
25 (Beckton-Dickenson, Oxford, UK), using the medium and conditions required by the
tumour cell line and allowed to adhere overnight. After this the cells were washed
with PBS before the addition of acetaminophen in 0.1 ml PBS (concentrations of 0.1
- 20 mM acetaminophen were dissolved in PBS by sonication) and then maintained
at 37°C. At the appropriate time points, cells were removed from the plates by
30 trypsinisation and collected by centrifugation. Cell viability was measured as ability
to exclude trypan blue. Cells were counted at x100 magnification using an Improved
Neubauer haemocytometer; all cell counts are the mean of duplicate determinations
of five fields from duplicate experiments.

5.5.2 ^3H -Thymidine Incorporation as a Measure of Cell Division

Transfected COS cells are either exposed to various concentrations of acetaminophen or incubated in the presence of 10mM acetaminophen and cell viability monitored with time. ^3H – thymidine (Amersham International UK, 1000Ci/mmol, 5 μCi per assay) , is added to treated and control cultures and aliquots removed and acid precipitable counts assessed by liquid scintillation using a Beckton Liquid Scintillation Counter.

10

5.6 Glutathione depletion.

The intracellular glutathione content, comprising reduced and oxidised forms of glutathione is measured using a kinetic assay in which glutathione in the presence of glutathione reductase catalyses the continuous reduction of 5,5'-dithio-bis(2-nitrobenzoic acid) by NADPH. The rate of the reaction is proportional to the concentration of glutathione. The reaction is monitored at 412 nm and quantified by comparison with standards.

20

5.7 Measurement of [^{14}C] Acetaminophen

Covalent binding of radioactivity to cell protein following exposure to radioactive acetaminophen. Cells are incubated for up to 90 min with [^{14}C]acetaminophen. After washing, cellular protein is precipitated with trichloroacetic acid and the precipitate washed extensively with 80% methanol to remove unbound radioactivity. The protein pellet is digested in sodium hydroxide, neutralised, and the bound radioactivity measured by scintillation spectroscopy.

30

5.9 Cell Culture of Stably Transfected Cell-lines

V79 MZ Chinese hamster cells were maintained in Dulbecco-Vogt's modified Eagle's Medium (DMEM) supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml) (all tissue culture reagents were obtained from Gibco BRL, Paisley, UK). H1A2 MZ cells, which are V79 MZ cells transfected with the human *CYP1A2* gene,⁹ were also maintained in supplemented DMEM with the addition of geneticin at a concentration of 4 mg/ml. SK-OV-3 cells were grown in DMEM supplemented with 15% FCS and 2 mM L-glutamine, without the addition of antibiotics. RPMI-1640 medium with 10% FCS, 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml) was required by the HCT116 cells. These cell lines were maintained at 37 °C with 100% humidity and 5% CO₂. MDA-MB-361 cells were grown in Leibovitz (L-15) medium supplemented with 15% FCS and 2 mM L-glutamine maintained at 37°C with 100% humidity and did not require CO₂. At confluence cells were removed from tissue culture flasks by incubation with trypsin-EDTA for 5 min, diluted 1 : 3-1 : 6 in fresh medium and seeded onto fresh flasks. The tumour cell lines were obtained from the European Collection of Cell Cultures.

5.9. Stably Transfected H1A2 MZ cells

The expression of human CYP1A2 in these cells was confirmed by measurement of 7-ethoxyresorufin O-deethylase and 7-methoxyresorufin O-deethylase activities on a cytosol-free protein fraction as described previously.⁹ The respective values obtained of 5.4 ± 0.1 and 12.1 ± 0.2 pmol/min/mg protein (n=6) are similar to those reported previously, i.e. 6.5 and 12.8 pmol/min/mg protein⁹ and no activity was detected in the parental V79 MZ cells. Further, the expression of human CYP1A2 in the cytosol-free protein fraction of H1A2 MZ cells, but not V79 MZ cells was also demonstrated by western blotting using an antibody specific for this P450 enzyme¹⁰ (data not shown).

6. RESULTS

We show that transient transfection of COS cells using LPA with a vector carrying CYP1A2 under the control of a promoter which shows enhanced expression in
5 tumour cells is capable of sensitising cells to therapeutically relevant concentrations of acetaminophen.

Figure 1 shows an acetaminophen titration comparing transfected COS cells with non-transfected control COS cells. Cells were transfected and allowed to recover and
10 express CYP1A2 for 48hrs. Although non-transfected parental cell -lines show some sensitivity to acetaminophen, as measured by tritiated thymidine incorporation, transfected cells show a significant increase in sensitivity. The apparent sensitivity of control cells to acetaminophen can be attributed to the fact that COS cells contain a significant amount of p450 activity which will result in the production of NABQI
15 the presence of acetaminophen. However by increasing the basal levels of p450, by transfection with CYP1A2 it is shown that the administration of less acetaminophen results in reduced cell viability for an equivalent amount of acetaminophen, please see Figure 1, 4mM acetaminophen concentration.

20 Figure 2 shows a COS cell viability time course in response to 10mM acetaminophen. COS cells were transfected and compared to non- transfected control cells over a period of 24hrs. The extent of acetaminophen sensitivity increases markedly during the first 4 – 8 hrs. This correlates with the expression of CYP1A2 as monitored by western blot, results not shown. The sensitivity of transiently
25 transfected COS cells is likely to be an underestimate of what may be achieved in stable cell-lines expressing CYP1A2 or *in vivo* in transgenic animal models since the vector DNA is susceptible to nuclease digestion resulting in a gradual decrease in potential sensitivity. This is, of course, is not shown by the control cells since the reduction in cell viability is the result of endogenous expression of p450 which is
30 ongoing.

These results indicate that transiently transfected COS cells can be sensitised to acetaminophen by expression of a vector carrying a gene encoding CYP1A2. These results are confirmed by producing cell lines stably transfected with CYP1A2 which is described below.

5

Incubating H1A2 MZ cells, which stably express CYP1A2, with a range of concentrations of acetaminophen (0.1-20 mM) for 6 h allowed the determination of cytotoxic concentrations (Fig. 1). No cytotoxicity was observed in the absence of acetaminophen or with 0.1 mM acetaminophen. However, after exposure to 1 mM acetaminophen viability fell to 62%. Incubation with 4 mM acetaminophen resulted in a further reduction in viability to 8%. Higher concentrations of acetaminophen resulted in a similar amount of cell killing, Figure 3. In contrast, incubation of V79 MZ cells, which lack CYP1A2, with acetaminophen resulted in no loss of cell viability, Figure 3. Therefore, as 4 mM acetaminophen was the minimum dose to give the maximum effect, this concentration was selected for further experiments.

10
15

To determine if the toxic metabolite produced by CYP1A2 had a cytotoxic effect on bystander cells incapable of activating acetaminophen, H1A2 MZ cells were mixed with V79 MZ cells before exposure to 4 mM acetaminophen. The percentage decline in total cell viability greatly exceeded the percentage of acetaminophen-activating cells in the mixture indicating a significant bystander effect, Figure 4. In the presence of 5% H1A2 MZ cells the viability of the mixed cell population was reduced to 52%, and as the proportion of H1A2 MZ cells was increased the number of viable cells in the mixture declined (Fig. 4, Table 1) and a near maximal effect was found with a mixture of an equal number of V79 MZ and H1A2 MZ cells, Figure 4. In contrast, no decline in cell viability was observed in V79 MZ cells incubated in 4 mM acetaminophen or H1A2 MZ cells incubated in phosphate-buffer saline (PBS) without acetaminophen (Figure 4, Table 1).

20
25
30

The susceptibility of tumour-derived cells to cytotoxicity produced by the activation of acetaminophen was investigated by mixing H1A2 MZ cells with SK-OV-3,

HCT116 and MDA-MB-361 cells and incubating them in the presence of 4 mM acetaminophen for 6 h. It was found that like V79 MZ cells, SK-OV-3 cells were highly sensitive as viability fell progressively as the proportion of H1A2 MZ cells was increased (Table 1). HCT116 cells showed a disproportionate decrease in viability when incubated with 5 and 10% H1A2 MZ cells, although with 50% H1A2 MZ cells the amount of cell killing could be accounted for by loss of H1A2 MZ cells alone (Table 1). However, MDA-MB-361 cells appeared to be highly resistant to cytotoxicity as the reduction in cell viability was similar to the proportion of H1A2 MZ cells present (Table 1).

10

To determine if the residual viable cells were programmed to die, as we have found previously,¹¹ attempts were made to culture the various cell types in normal growth medium after they had been exposed to acetaminophen for 6 h in the presence of the activating H1A2 MZ cells. It was found that after 24 h in culture, the viability of V79 MZ, SK-OV-3 and HCT116 cells mixed with as little as 5% H1A2 MZ cells fell to zero (Table 1). Only MDA-MB-361 cells showed resistance to cell killing, although even with these cells viability was reduced to 18% in cultures comprising an equal number of MDA-MB-361 and H1A2 MZ cells and no viable cells were found after 48 h (Table 1). Nevertheless, with fewer H1A2 MZ cells present viability increased with time, presumably as the number of dividing MDA-MB-361 cells increased during culture.

15

20

7. DISCUSSION

Acetaminophen can be activated by oxidation catalysed by human CYP1A2 to form the cytotoxic compound NABQI. The combination of acetaminophen as prodrug and CYP1A2 as activating enzyme has a potential application in GDEPT. It has been demonstrated here that a sufficient amount of NABQI produced in cells transfected with human CYP1A2 to cause cytotoxicity. Further, enough NABQI is released from activating cells to cause cytotoxicity in neighbouring cells. Such a bystander effect was readily demonstrated in V79 MZ cells. However, human tumour-derived cells showed a range of sensitivities. An extensive bystander effect was found using SK-

30

- OV-3 cells, an ovarian tumour derived cell line, whereas, HCT-116 cells, which are derived from a colon tumour, appeared to be somewhat more resistant to the cytotoxic effect of NABQI when assessed immediately after a 6 h incubation period. However, both of these tumour cell types appeared to have been markedly damaged by exposure to NABQI as they failed to survive in culture. On the other hand, the MDA-MB-361 cells, which originate from a breast tumour, displayed resistance of the cytotoxic effect of NABQI, with only those cells exposed to the highest concentration being affected.
- NABQI is capable of arylating and oxidising protein thiol groups, although studies with thiol reductants such as dithiothreitol¹¹ and N-acetylcysteine¹² suggested that the reversible oxidation of thiols (i.e. "oxidative stress") rather than arylation is responsible for cell death from acetaminophen.⁶ Irrespective of the exact mechanism, the key factors that determine the toxicity of acetaminophen are the rate of production of NABQI as determined by the activity of the relevant cytochrome P450 enzymes and the starting level and extent of depletion of GSH. Thus rat liver is relatively resistant to acetaminophen, but not pre-formed NABQI, because the rate of formation of the reactive metabolite is insufficient, even at very high concentrations of acetaminophen, to deplete GSH.¹³ In contrast, hamsters are very sensitive because acetaminophen is rapidly and extensively oxidised to NABQI. Human liver hepatocytes exhibit a range of sensitivities which correlate with the rate of oxidation of acetaminophen to NABQI.¹³ Toxicity in overdosed individuals is confined to the liver which is the only organ that has the required level of enzyme activity to generate NABQI to deplete GSH, a prerequisite for cell damage and death. The hepatotoxicity of acetaminophen can be greatly increased in all species by prior depletion of GSH with chemicals such as diethylmaleate.¹⁴ Thus the toxicity of acetaminophen is dependent upon the balance between the activity of the NABQI-generating enzyme and the concentration of GSH.
- GSH concentrations in breast tumours (913nmol/g tissue) are two-fold greater than in normal breast tissue¹⁵ but are less than 20% of those found in normal human liver

(>5000 nmol/g tissue). Thus if tumour cells can be made to express NABQI-producing activity similar to human liver, therapeutic doses of acetaminophen should be selectively cytotoxic to the tumour cells. In addition, it will be possible to selectively protect the liver from any toxic effects of acetaminophen by oral administration of GSH precursors such as methionine or N-acetylcysteine¹⁶ that elevate GSH in the liver but not other tissues.¹⁷

It might be possible to increase the efficiency of the enzyme activating system by replacing human CYP1A2 with another P450 enzyme with a greater capacity for acetaminophen activation. Although human CYP2E1 and CYP3A4 are known to catalyse this reaction,⁷ the rates relative to CYP1A2 at high concentrations of acetaminophen have yet to be determined. Alternatively, the orthologous rodent forms of CYP1A2, CYP2E1 or CYP3A4 may provide the source of a more efficient enzyme.

REFERENCES

1. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. *Gene Ther.* 1995;2:702-709
2. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. *Gene Ther.* 1994;1:170-175
3. Davidson DG, Eastham WN. Acute liver necrosis following overdose of acetaminophen. *Br Med J.* 1966;5512:-1990.
4. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. *J Pharmacol Exp Ther.* 1973;187: 211-217

5. Miner DJ, Kissinger PT. Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism. *Biochem Pharmacol.* 1979;28:3285-3290.
- 5 6. Boobis AR, Fawthrop DJ, Davies DS. Mechanisms of cell death. *Trends Pharmacol Sci.* 1989;10:275-280.
7. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, Yang CS. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. *Chem Res Toxicol.* 1993;6:511-518.
- 10 8. Thatcher NJ, Murray S, Edwards RJ, Davies DS. Measurement of N-acetylbenzoquinoneimine formation by human hepatic microsomes. 12th *International Symposium on microsomes and Drug Oxidations* 1998; abstract 74.
- 15 9. Wolfel C, Heinrich-Hirsch B, Schulz-Schalge T, Seidel A, et al. Genetically engineered V79 Chinese hamster cells for stable expression of human cytochrome P450IA2. *Eur J Pharmacol.* 1992;228:95-102
- 20 10. Edwards RJ, Murray BP, Singleton AM, Murray S, Davies DS, Boobis AR. Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. *Biochem Pharmacol* 1993;46:213-220.
- 25 11. Tee LB, Boobis AR, Huggett AC, Davies DS. Reversal of acetaminophen toxicity in isolated hamster hepatocytes by dithiothreitol. *Toxicol Appl Pharmacol.* 1986;83:294-314.
- 30

12. Boobis AR, Tee LB, Hampden CE, Davies DS. Freshly isolated hepatocytes as a model for studying the toxicity of acetaminophen. *Food Chem Toxicol.* 1986;24:731-736.
- 5 13. Tee LB, Davies DS, Seddon CE, Boobis AR. Species differences in the hepatotoxicity of acetaminophen are due to differences in the rate of conversion to its cytotoxic metabolite. *Biochem Pharmacol.* 1987;36: 1041-1052.
- 10 14. Potter WZ, Thorgeirsson SS, Jollow DJ, Mitchell JR. Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. *Pharmacology.* 1974;12: 129-143.
- 15 15. Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumours and normal tissue. *Cancer.* 1993; 72: 783-787.
- 16 16. McLean AE, Day PA. The effect of diet on the toxicity of acetaminophen and the safety of acetaminophen-methionine mixtures. *Biochem Pharmacol.* 1975; 24: 37-42.
- 20 17. Aebi S, Lauterburg BH. Divergent effects of intravenous GSH and cysteine on renal and hepatic GSH. *Am J Physiol.* 1992; 263:348-352.

Table 1.

Cell type	H1A2 MZ cells (%)	Viability (%)			
		0 h	6 h	24 h	48 h
V79 MZ	0	99 ± 1	94 ± 7	98 ± 1	-
	5	98 ± 1	52 ± 5***	0 ± 0***	-
	10	98 ± 1	39 ± 6***	0 ± 0***	-
	25	97 ± 2	20 ± 4***	0 ± 0***	-
	50	96 ± 3	15 ± 7***	0 ± 0***	-
SK-OV-3	0	97 ± 1	98 ± 2	96 ± 3	-
	5	98 ± 1	55 ± 2***	0 ± 0***	-
	10	98 ± 1	43 ± 7***	0 ± 0***	-
	25	97 ± 1	22 ± 11***	0 ± 0***	-
	50	98 ± 1	16 ± 9***	0 ± 0***	-
HCT116	0	96 ± 1	96 ± 5	96 ± 2	-
	5	98 ± 1	69 ± 9***	0 ± 0***	-
	10	98 ± 1	60 ± 6***	0 ± 0***	-
	25	97 ± 1	56 ± 4***	0 ± 0***	-
	50	98 ± 1	42 ± 6***	0 ± 0***	-
MDA-MB-361	0	96 ± 1	98 ± 4	95 ± 3	97 ± 1
	5	98 ± 2	85 ± 2**	84 ± 7**	92 ± 4
	10	96 ± 3	74 ± 7***	81 ± 9**	94 ± 7
	25	97 ± 1	70 ± 11***	78 ± 9***	91 ± 6
	50	98 ± 3	42 ± 4***	18 ± 5***	0 ± 0***

ART 34 AMDT

Claims

- 1 A method for use in the treatment of cancer comprising:
- 5 i) administering to a mammal an effective amount of at least one vector capable of transfecting at least one tumour cell characterised in that said vector includes at least one P450 gene, or the effective part thereof, the expression of which is controlled by a promoter sequence, or the effective part thereof, which shows substantially tumour cell specific expression; and
- 10 ii) administering a therapeutically effective amount of at least acetaminophen, or a structurally related derivative thereof.
2. A method according to Claim 1 characterised in that said mammal is human.
- 15 3. A method according to Claims 1 or 2 characterised in that said vector is a eukaryotic expression vector.
4. A method according to any of Claims 1 – 3 characterised in that said vector is a viral based vector.
- 20 5. A method according to Claim 4 characterised in that said vector is a hybrid viral vector.
6. A method according to Claim 4 or 5 characterised in that said viral based vector is
- 25 selected from at least one of the following: adenovirus; retrovirus; adeno associated virus; herpesvirus; lentivirus; or baculovirus.
7. A method according to any of Claims 1 – 6 characterised in that said tumour promoter is selected from at least one of : TRP-1; HER2; HER3; ERBB2; ERBB3; CEA;
- 30 MUC1; or α -fetoprotein; Rous sarcoma virus long terminal repeat; cytomegalovirus promoter; murine leukaemia long terminal repeat; simian virus 40 early and late promoters; herpes simplex virus thymidine kinase promoter; prostate specific antigen promoter (PSA); zilin gene promoter; pancreatic amylase promoter; tyrosinase related peptide promoter; tumour rejection antigen precursor promoters.

35

8. A method according to Claim 7 characterised in that said promoter is a hybrid promoter of at least the effective parts of at least two tumour cell specific promoters.

5 9. A method according to any of Claims 1 – 8 characterised in that said P450 gene is of mammalian origin.

10. A method according to Claim 9 characterised in that said P450 gene is of human origin.

10 11. A method according to Claim 9 characterised in that said P450 gene is of rodent origin.

12. A method according to Claim 10 characterised in that said human P450 gene is selected from : CYP1A2; CYP2E1; or CYP3A4.

15 13. A method according to Claim 11 characterised in that said P450 gene is selected from: rodent CYP1A2; rodent CYP2E-1; or rodent CYP3A4.

20 14. A method according to Claims 1-14 characterised in that said tumour cell is selected from at least one of the following cancers: breast; pancreatic; ovarian; cervical; lung; hepatic; renal; testicular; prostate gastrointestinal; glioma; melanoma; bladder; lymphoma; leukaemia; epithelial, mesothelial; retinal.

25 15. A vector for use in the method according to Claims 1 – 14.

16. Acetaminophen in combination with a vector as defined in any of Claims 1 – 15 for use in the treatment of cancer.

30 17. A method for use in the treatment of cancer comprising:

35 i) administering to a mammal an effective amount of at least one vector, capable of transfecting at least one tumour cell, characterised in that said vector includes at least one P450 gene, or the effective part thereof, the expression of which is controlled by a promoter sequence, or the effective part thereof, which shows substantially tumour cell specific expression;

- ii) administering an effective amount of at least one agent capable of modulating the amount of glutathione in said mammal; and
- iii) administering a therapeutically effective amount of acetaminophen, or a structurally related derivative thereof.

5

18. A method according to Claim 17 characterised in that said agent is selected from at least one of: methionine; acetylcysteine.

10

19. A vector as defined in any of Claims 1 - 15 and a therapeutically effective amount of acetaminophen, or a structurally related derivative thereof, as a combined medicament for the simultaneous, separate or sequential use in the treatment of cancer.

15

20. A kit for use in the treatment of cancer comprising a vector as defined in any of Claims 1 - 15; acetaminophen; and, optionally an excipient, carrier or diluent.

20

Figure 1




Figure 2




FIGURE 3




FIGURE 4




FIGURE 6

GTTTGACAGCTTATCATCGACTGCACGGTGACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCTGTGGTATGGCTGT
 GCAGGTTCGTAAATCACTGCATAATTCGTGTGCTCAAGGCGCACTCCCGTCTGGATAATGTTTTTGGCGCGACATCAT
 AACGGTTCCTGGCAAATATTCTGAAATGAGCTGTTGACAAATTAATCATCGGGCTCGTATAATGTGTGGAATTGTGAGCGGA
 TAACAATTTACACAGGAAACAGACCATGGAGCAGAAGCTGATTCCGAGGAGGACCTGGGATCCGAATCAAGCTTCCC
 GGGGTTCGACATCGATTAGACTAGTCTAGACGGCGCGGCAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTACGCCTG
 ATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCACCTGA
 CCCCATGCCGAATCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAAGTAGGGAAGTCC
 AGGCATCAAAATAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCCGTGAACGCTCTCCT
 GAGTAGGACAAATCCGCCGGGAGCGGATTGTAACGTTGCGAAGCAACGCCCGGAGGGTGGCGGGCAGGACGCCGCCAT
 AAAGTCCAGGCATCAAAATTAAGCAGAAGGCCATCTGACGGATGGCCTTTTTCGTTTCTACAAACTCTTTTGTAT
 TTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
 AGTATGAGTATTCAACATTTCCGTGTGCCCTTATTCCTTTTTCGGGCATTTTCCTTCTGTTTTCGCTCACCAGA
 AACGCTGGTGAAGTAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTA
 AGATCCTTGAGAGTTTTCCGCCGAAGACGTTTTCCAATGATGAGCACTTTAAAGTTCTGCTATGTGGCGCGGTATTA
 TCCCGTGTGACGCCGGGCAAGAGCAACTCGGTGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGT
 CACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGTGCCATAACCATGAGTGATAACACTGCGG
 CCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTCACAACATGGGGGATCATGTAACCTGC
 CTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAACGACGAGCGTGACACCAGATGCCTACAGCAATGGCAAC
 AACGTTGCGCAAACTATTAAGTGGCAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGCGGATA
 AAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGTGGCTGGTTTATGCTGATAAATCTGGAGCGCGTGAGCGTGGG
 TCTCGCGGTATCATTCGAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGC
 AACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTT
 ACTCATATATACTTTAGATTGATTAAAACTTCAATTTTAAATTTAAAGGATCTAGGTGAAGATCCTTTTGATAATCTC
 ATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGA
 TCCTTTTTTCTGCGCGTAATCTGTGCTTGAACAAAAAACACCACCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAG
 AGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTACGAGAGCGCAGATACCAAACTACTGCTCTTAGTGTAGCCGTAG
 TTAGGCCACCACTTCAAGAACTCTGTAGCACCAGCTACATACCTCGCTCTGCTAATCTGTTACCAAGTGGCTGCTGCCAG
 TGGCGATAAGTCTGTCTTACCAGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGGTGAACGGGGG
 GTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCC
 ACGCTTCCCGAAGGGAGAAAGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTC
 AGGGGGAAACGCGCTGGTATCTTTATAGTCTGTGCGGTTTTCCGCCACCTCTGACTTGAGCGTCGATTTTGTGATGCTGT
 CAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCCGCCCTTTTACGGTTCCTGGCCTTTTGTGCGCCTTTTGTCTAC
 ATGTTCTTCTGCGTTATCCCTGATTCTGTGGATAACCGTATTACCGCTTTGAGTGAGCTGATACCGCTCGCCGAG
 CCGAACGACCGAGCGCAGCGAGTCACTGAGCGAGGAAGCGGAGAGCGCTGATGCGGTATTTCTCCTTACGCATCTGT
 GCGGTATTTACACCGCATATGGTGCACCTCTCAGTACAATCTGCTGATGCCGCATAGTTAAGCCAGTATACACTCCGC
 TATCGCTACGTGACTGGGTATGGTGCGCCCGACACCGCCAACACCGCTGACGCGCCTGACGGGCTTGTCTGCTC
 CCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGTTCATACCGAAACG
 CGCGAGGCAGCAGATCAATTCGCGCGCAAGGCGAAGCGGCATGCATTTACGTTGACACCATCGAATGGTGCAAAACCTT
 TCGCGGTATGGCATGATAGCGCCCGAAGAGAGTCAATTCAGGTGGTGAATGTGAAACAGTAACGTTATACGATGTCG
 CAGAGTATGCCGGTGTCTTATCAGACCGTTTCCCGCGTGGTGAACAGGCCAGCCAGCTTCTCGGAAAACGCGGGAA
 AAAGTGAAGCGCGGATGGCGGAGCTGAATTACATTTCCCAACCGCGTGGCACAACAAGTGGCGGGCAACAGTCTGTGCT
 GATTGGCGTGGCACCTCCAGTCTGGCCCTGCACGCGCGCTGCGAAATGTGCGCGCGATTAAATCTCGCGCGGATCAAC
 TGGGTGCCAGCGTGGTGGTGTGATGGTAGAAGCAAGCGCGCTGAAGCCTGTAAAGCGCGGTTGACAATCTTCTCGCG
 CAACGCGTCAGTGGGCTGATCAATATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGT
 TCCGGCGTTATTTCTGATGTCTTGACCAGACACCAATCAACAGTATTATTTCTCCCATGAAGACGGTACGCGACTGG
 GCGTGGAGCATCTGTCGATTTGGGTACCAGCAATCGCGCTGTAGCGGGCCATTAAAGTTCTGTCTCGCGCGCTCTG
 GTCTGGTGTGGTGGCATAAATATCTCACTCGCAATCAAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCAT
 GTCCTGTTTCAACAAACCATGCAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGG
 CGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGGCGATATCTCGGTAGTGGGATACGACGATACC
 GAAGACAGCTCATGTTATATCCCGCGTTAACCAACCATCAAAACAGGATTTTCGCTGCTGGGGCAACACGCGTGACCG
 CTTGCTGCAACTCTCTCAGGGCCAGCGGTGAAGGGCAATCAGCTGTTGCCGCTCTCACTGGTGAAAAAGAAAAACACCC
 TGGCGCCCAATACGCAAAACCGCTCTCCCGCGCGTTGGCCGATTCATTAATGACAGCTGGCAGCAGAGTTTCCCGACTG
 GAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCGCGAATTGATCTG

DECLARATION AND POWER OF ATTORNEY (For Use with Application Data Sheet)

As the below named inventor(s), I/we declare that:

This declaration is directed to:


 The attached application, or
 X Application No. PCT/GB99/04268, filed on 30 December 1999,
 X as amended on 16 January 2001 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable;


I/we hereby appoint the practitioners at **CROWELL & MORING L.L.P.**, whose Customer Number is:



as my/our attorneys to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith; and

All statements made herein of my/our own knowledge are true; all statements made herein on information and belief are believed to be true, and further these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME(S) of INVENTOR(S)

Signature: 
Inventor one: **Donald DAVIES**
Citizen of: United Kingdom

Date: 1st October 2001